Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2024-05-10 Board/Management Inform…
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of a CEO and the appointment of an interim CEO, which falls under changes in senior management. The key section is Item 5.02, which relates to departure and appointment of directors or principal officers. There is no financial data or report attached, and the document is not an earnings release or annual report. Therefore, this filing is best classified as Board/Management Information (MANG). The document length is just over 5,000 characters, but the content clearly focuses on management changes, not report publication or regulatory filings. Confidence is high due to the clear and explicit description of management changes.
2024-05-10 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by Collegium Pharmaceutical, Inc. It announces the issuance of a press release with financial results for the quarter ended March 31, 2024, and an earnings presentation. The document itself does not contain the financial results but rather furnishes these materials as exhibits. The length is 3749 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase "issued a press release announcing its financial results" and "released an earnings presentation" indicates this is an announcement of earnings information, not the earnings release itself. According to the "Menu vs Meal" rule, this is a Regulatory Filing (RNS) because it is a current report announcing the release of earnings information and presentation, not the earnings release document itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-05-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 26, 2024, by Collegium Pharmaceutical, Inc. It reports the entry into a material definitive agreement with Hikma Pharmaceuticals USA Inc. regarding authorized generic rights for certain pharmaceutical products. The content focuses on the description of the agreement terms, rights granted, and conditions for termination. There are no financial statements or detailed financial performance data included. The document is a current report disclosing a significant corporate event (entry into a material definitive agreement), which fits the category of Capital/Financing Update (CAP) as it relates to a material agreement affecting the company's product commercialization and revenue streams. It is not an annual or quarterly report, audit report, earnings release, or other categories. The length (5591 characters) and content confirm it is a substantive filing rather than a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-29 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 11, 2024. It announces that Collegium Pharmaceutical, Inc. has called for redemption all of its outstanding Convertible Senior Notes due 2026. The document includes details about the redemption price, redemption date, and conversion deadline. It explicitly states that this Form 8-K is not the notice of redemption itself but references a Notice of Redemption dated the same day. The content focuses on a capital structure event related to debt redemption and financing activities. There are no financial statements or quarterly/yearly financial results presented, nor is it a full annual or interim report. The primary subject is an update on financing activity (redemption of convertible notes). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4173 characters, which is sufficient to contain substantive information rather than just a brief announcement or certification, supporting this classification.
2024-04-11 English
ARS
Annual Report
2024-04-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.